Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir

NCT02345707 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG: Cabotegravir 30 mg current formulation
DRUG: Cabotegravir 30 mg micronized new formulation 500 M
DRUG: Cabotegravir 30 mg unmicronized new formulation 500 U
DRUG: Cabotegravir 30 mg micronized new formulation 650 M
DRUG: Cabotegravir 30 mg unmicronized new formulation 650 U

Sponsor

ViiV Healthcare